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Objectives: Nonadherence to prescription medications has been shown to be significantly
influenced by three key medication-specific beliefs: patients’ perceived need for the prescribed
medication, their concerns about the prescribed medication, and perceived medication
affordability. Structural equation modeling was used to test the predictors of these three proximal
determinants of medication adherence using the proximal–distal continuum of adherence drivers
as the organizing conceptual framework.
Methods: In Spring 2008, survey participants were selected from the Harris Interactive Chronic Illness
Panel, an internet-based panel of hundreds of thousands of adults with chronic disease. Respondents
were eligible for the survey if they were aged 40 years and older, resided in the US, and reported having at least one of six chronic diseases: asthma, diabetes, hyperlipidemia, hypertension, osteoporosis,
or other cardiovascular disease. A final sample size of 1072 was achieved. The proximal medication
beliefs were measured by three multi-item scales: perceived need for medications, perceived medication concerns, and perceived medication affordability. The intermediate sociomedical beliefs and
skills included four multi-item scales: perceived disease severity, knowledge about the prescribed
medication, perceived immunity to side effects, and perceived value of nutraceuticals. Generic health
beliefs and skills consisted of patient engagement in their care, health information-seeking tendencies,
internal health locus of control, a single-item measure of self-rated health, and general mental health.
Structural equation modeling was used to model proximal–distal continuum of adherence drivers.
Results: The average age was 58 years (range = 40–90 years), and 65% were female and 89%
were white. Forty-one percent had at least a four-year college education, and just under half
(45%) had an annual income of $50,000 or more. Hypertension and hyperlipidemia were each
reported by about a quarter of respondents (24% and 23%, respectively). A smaller percentage
of respondents had osteoporosis (17%), diabetes (15%), asthma (13%), or other cardiovascular
disease (8%). Three independent variables were significantly associated with the three proximal
adherence drivers: perceived disease severity, knowledge about the medication, and perceived
value of nutraceuticals. Both perceived immunity to side effects and patient engagement was significantly associated with perceived need for medications and perceived medication concerns.
Conclusion: Testing the proximal–distal continuum of adherence drivers shed light on specific areas where adherence dialogue and enhancement should focus. Our results can help to
inform the design of future adherence interventions as well as the content of patient education
materials and adherence reminder letters. For long-term medication adherence, patients need
to autonomously and intrinsically commit to therapy and that, in turn, is more likely to occur
if they are both informed (disease and medication knowledge and rationale, disease severity,
consequences of nonadherence, and side effects) and motivated (engaged in their care, perceive
a need for medication, and believe the benefits outweigh the risks).
Keywords: compliance, prescription medications, medication beliefs, treatment beliefs
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Introduction
Over the past 40 years, numerous conceptual models have
been proposed to explain medication nonadherence.1 A short
listing of models that have been tested in relation to medication adherence include the Health Belief Model,2 the Theory
of Reasoned Action,3 the Theory of Planned Behavior,4
the Transtheoretical Model, 5 the Necessity-Concerns
Framework,6 the Information-Motivation-Behavioral Skills
model,7 and the Information-Motivation-Strategy model.8
Most of these frameworks belong to the family of models subsumed under social-cognitive theory,1 and these models have
incrementally built on the conceptual and empirical learning
of one another. At the heart of all of these frameworks, as well
as others, are two guiding assumptions: (1) individuals make
decisions about prescription medications (ie, patients do not
passively and reflexively obey physician recommendations
about prescription medications); and (2) medication adherence is influenced by an array of patient beliefs, attitudes,
skills, and experiences.
In 2009, the Proximal–Distal Continuum of Adherence
Drivers model was proposed.9 In the proximal–distal continuum, it was asserted that some adherence determinants
are nearer or closer to patients’ medication-taking decisions
(proximal) while others are more removed (further from)
patients’ adherence decisions. The aim of the proximal–
distal continuum was to organize the numerous hypothesized
medication adherence drivers along an etiological continuum
of determinants ranging from those shown to have strong
empirical relationships with adherence (proximal drivers) to
those with weaker relationships (distal drivers). In short, the
proximal–distal continuum consists of an etiological hierarchy of hypothesized adherence drivers in order to account for
medication adherence in a multifactorial manner.
The proximal–distal continuum is based upon three fundamental tenets. First, an adherent “personality” does not
exist – the same individual can be adherent to one medication, not fill a second medication prescription, decide to stop
taking a third medicine without the advice of their provider,
and be careless taking a fourth medication.9 A growing
body of research has demonstrated that individual patients
have different adherence patterns and levels for assorted
medications, both within a therapeutic class10–12 as well as
across therapeutic areas.13–16 Intraindividual variability in
medication taking occurs because patients have different
beliefs about different prescribed medications and their
attendant diagnosed conditions. Second, patient beliefs,
skills, and experiences that influence medication adherence
can be either specific to a prescribed medication or disease
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or they can be generic in nature (ie, nonspecific to a prescribed medication or disease). In general, patient beliefs,
skills, and experiences specific to a prescribed medication
or disease tend to be more predictive of adherence than
generic psychosocial beliefs and skills.9,17–21 Third, for
many patients, a new diagnosis and the attendant prescribed
therapy represents uncertainty and is a threat to the status
quo.22 The short-term benefits of prescription-medication
therapy can seem intangible to patients, especially to those
with asymptomatic chronic disease. The long-term benefits
of prescription medications are probabilistic and can be
so distant in the future that patients may heavily discount
them. Viewed through the uncertainty lens, nonadherence
can make sense from the patient perspective because taking prescription medications represents a risky prospect
in the short term (short-term financial, psychological, and
opportunity costs, and risk of side effects) with uncertain
long-term benefits (probabilistic reductions in mortality,
morbidity, and complications) compared to the status quo
(health as it is).23
At the proximal end of the continuum are patients’ beliefs
about the prescribed medication (Figure 1). Research over
the past 20 years has consistently demonstrated that patients’
beliefs about a prescribed medication are potent predictors
of medication adherence. Next, etiologically, are patients’
sociomedical and disease-related beliefs, skills, and experiences which are hypothesized to be direct determinants of
patients’ proximal medication beliefs. Patients’ generic
beliefs, skills, and experiences are hypothesized to directly
influence the disease-related and sociomedical beliefs.
Finally, the most distal variables encompass demographic
characteristics. Meta-analytic research has demonstrated
weak associations between sociodemographic characteristics
and adherence.24
A large body of research has provided evidence
about the relative influence of the myriad adherence
drivers potentially subsumed under the proximal–distal
c ontinuum. The vast majority of these studies have
examined medication adherence as the outcome variable.
However, few studies have modeled the determinants of
proximal medication beliefs – beliefs demonstrated by
past research to be powerful predictors of medication
adherence. N onadherence to prescription medications
has been shown to be significantly influenced by three
key medication-specific beliefs: patients’ perceived need
for the prescribed medication,9,18,19,25–37 their concerns about
the prescribed medication,9,18,19,26,29,30,33,34,38–47 and perceived
medication affordability.9,48–55 We used structural equation
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Demographics
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Perceived medication
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adherence
drivers
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Figure 1 The proximal–distal continuum of adherence drivers.

 odeling (SEM) to test the predictors of these three
m
proximal determinants of medication adherence. The goal
of testing the proximal–distal continuum was to shed light
on the origins of the three key proximal medication beliefs.
This information can contribute insights as to how future
adherence interventions may be made more efficacious by
identifying underlying mechanisms influencing perceived
need for medications, perceived medication concerns, and
perceived medication affordability.

Methods
Study design

Sampling procedure
As described in detail elsewhere,9 in Spring 2008, survey
participants were selected from the Harris Interactive
Chronic Illness Panel, an internet-based panel of hundreds
of thousands of adults with chronic disease. Respondents
were eligible for the survey if they were aged 40 years and
older, resided in the US, and reported having at least one of
six chronic diseases prevalent among US adults: asthma,
diabetes, hyperlipidemia, hypertension, osteoporosis, or other
cardiovascular disease (CVD) (eg, angina, myocardial infarction, congestive heart failure). The six chronic diseases reflect
a mix of symptomatic and asymptomatic conditions. They
are some of the most highly prevalent conditions in the US56
and are associated with a significant clinical and economic
burden for the US health care system.57 If eligible respondents
reported more than one of the six target conditions, one was
randomly selected as the index (study) disease. Panel members responding to an e-mail invitation were instructed to read
the informed consent form and click on yes if they agreed to
participate. The protocol for the survey was approved by the
Essex Internal Review Board. A 26.5% survey contact rate

Patient Preference and Adherence 2012:6

(per standards recommended by the American Association
for Public Opinion Research)58 was achieved. A total of 1072
adults completed the survey.

Survey content
The proximal, intermediate, and distal variables were all
collected during a single survey administration. The proximal medication beliefs were measured by three multi-item
scales: perceived need for medications (k = 12, Cronbach’s
alpha = 0.96, illustrative item: “I am convinced of the
importance of my prescription medication.”);9 perceived
medication concerns (k = 10, Cronbach’s alpha = 0.90 items,
illustrative item: “I worry that my prescription medication
will do more harm than good to me.”);9 and perceived
medication affordability (k = 7, Cronbach’s alpha = 0.97,
illustrative item “I feel financially burdened by my out-ofpocket expenses for my prescription medication.”).9 The
intermediate disease-related and sociomedical beliefs and
skills included four multi-item scales: perceived disease
severity (k = 3, Cronbach’s alpha = 0.76, illustrative item:
“I think that my condition is severe.”); knowledge about
the index medication (k = 9, Cronbach’s alpha = 0.92,
illustrative item: “I understand exactly what the medication
prescribed for me will do for me.”); perceived immunity
to side effects (k = 3, Cronbach’s alpha = 0.90, illustrative
item: “My chances of experiencing negative side effects
from a prescription drug are high.”); and perceived value
of nutraceuticals (ie, vitamins, minerals, and supplements)
(k = 7, Cronbach’s alpha = 0.92, illustrative item: “For me
personally, I believe that vitamin, mineral, and herbal supplements can achieve better health results than prescription
drugs can.”). Generic health beliefs and skills were measured
by patient engagement in their care (k = 14, Cronbach’s
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alpha = 0.97, illustrative item “My doctor and I have a real
partnership in my health care.”); health information-seeking
tendencies (k = 5, Cronbach’s alpha = 0.91, illustrative item:
“I actively seek out information on my illnesses.”); internal
health locus of control using Wallston’s measure (k = 10,
Cronbach’s alpha = 0.89);59 general mental health using the
Mental Health Inventory (k = 5, Cronbach’s alpha = 0.88);60
and a single-item measure of self-rated health (the “excellent-to-poor” item from the Medical Outcomes Study [MOS]
Short-Form Health Survey [SF-36]).60 Evidence of the validity of these measures vis á vis the criterion of medication
adherence has been previously published.9,61–64 With the
exception of the Mental Health Inventory (a six-point scale
ranging from “all of the time” to “none of the time”), health
locus of control (a six-point scale ranging from “strongly
disagree” to “strongly agree”), and the “excellent-to-poor”
item (excellent, very good, good, fair, or poor), all items
used a six-point categorical rating scale ranging from “agree
completely” to “disagree completely.” Each multi-item scale
was computed using Likert’s method65 of summated ratings
in which each item is equally weighted and raw item scores
are summed into a scale score. All scale scores were linearly
transformed to a 0–100 metric, with 100 representing the
most favorable belief or state, 0 the least favorable, and
scores in between representing the percentage of the total
possible score.
Demographic variables were included in the model.
Age was measured as a continuous variable. Gender and
race were coded as 1 = female vs 0 = male and 1 = white vs
0 = nonwhite, respectively. Education was measured as a
six-level interval variable with higher values indicating
higher education. Income was measured with an 11-level
interval variable with higher values indicating higher
income. Each disease indicator was coded as 1 = present vs
0 = not present with hypertension selected as the reference
group because it had the largest sample size of the six
diseases.

Statistical analysis
Survey noncontact analysis
Logistic regression was used to assess differences between
Chronic Illness Panel members with valid e-mail addresses
who did and did not respond to the survey invitation
(ie, survey noncontact bias per standards recommended by
the American Association for Public Opinion Research).58
Independent variables for the logistic regression were age,
gender, race, education, income, and geographic region of
residence.

792

Powered by TCPDF (www.tcpdf.org)

submit your manuscript | www.dovepress.com

Dovepress

Structural equation modeling (SEM)
SEM was used in this analysis because some variables were
both endogenous and exogenous, and traditional multivariate
regression would not efficiently test the path relationships
in one model. Twelve equations (three equations with the
proximal beliefs as dependent variables, four equations with
the intermediate beliefs and skills as dependent variables,
and five equations with the generic beliefs, states, and skills
as the dependent variables) were specified to represent the
hypothesized relationships among the variables, which were
treated as measured indicators of respondents’ beliefs, states,
and skills (see Figure 1). A single multivariate path model
of these structural equations66–69 was estimated by modeling
the covariance matrix among the observed variables. As
shown in Figure 1, the three proximal beliefs were specified to be associated with the intermediate, disease-related
beliefs and skills, which in turn were associated with the
distal generic beliefs and skills, and in turn with demographic
characteristics.
SEM model fitting was performed in two steps. The first
step was the execution of a full model to include all variables specified in the proximal–distal continuum (Figure 1).
The final model, presented in Tables 2–4, includes only
statistically-significant variables. Statistical significance,
goodness-of-fit indices, and modification indices were used
to guide the final model.
All available data were used in the analysis and were
used as input into Mplus© software (version 6.1; Muthén
and Muthén, Los Angeles, CA).70 Full information maximum likelihood with the Mplus MLR estimator was used
to estimate path coefficients and standard errors robust
to nonnormality. The chi-square test and three fit indices
(comparative fit index [CFI], root mean square error of
approximation [RMSEA], and the standardized root mean
square residual [SRMR]) provided an assessment of model
fit. Good model fit was identified with chi-square ratio , 3.0,
CFI . 0.95, RMSEA , 0.05, and SRMR , 0.08. 71
Correlated error terms were freely estimated within each
domain (generic beliefs, intermediate beliefs, and proximal
beliefs). Mplus uses model modification indices to determine
what parameters should be added to the model to improve
model fit. Modification indices are chi-square statistics with
one degree of freedom for the fixed and constrained parameters in a structural equation model. They estimate the change
in the improvement in the likelihood-ratio chi-square statistic
for the model if the corresponding parameter is respecified
as a free parameter. Modifications that improve model fit
are regarded as potential changes that can be made to the
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SEM model. The hypothesized relationships were tested
based on their statistical significances of path coefficients.
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Results
Survey noncontact
A 26.5% contact rate was achieved. Compared to those who
were invited but did not respond to the survey, those successfully contacted were more likely to be age 55 and older,
white, and college educated.9

Sample characteristics
As shown in Table 1, the average age of respondents was
58 years (range = 40–90 years), and 65% were female and
Table 1 Sociodemographic characteristics
Sociodemographic characteristic
Mean age (±SD)
Median age (±IQR)
Age 65+
Female
White
Black
Hispanic
Other race
Less than high school
High school graduate
Some college but no degree
Bachelor’s degree
Some graduate school but no degree
Graduate or professional degree
Income , $15,000
Income $15,000–$24,999
Income $25,000–$34,999
Income $35,000–$49,999
Income $50,000–$74,999
Income $75,000–$99,999
Income $100,000–$124,999
Income $125,000–$149,999
Income $150,000–$199,999
Income $200,000–$249,999
Income . $250,000
Asthma
Diabetes
Hyperlipidemia
Hypertension
Osteoporosis
Other cardiovascular disease
Self-rated health
Excellent
Very good
Good
Fair
Poor

N = 1072
N

%

325
695
928
56
30
24
12
167
450
177
88
178
62
130
149
160
177
117
49
27
22
10
11
144
157
249
257
180
85

58.3 (10.4)
58.0 (17.0)
30.3%
64.8%
89.4%
5.4%
2.9%
2.3%
1.1%
15.6%
42.0%
16.5%
8.2%
16.6%
6.8%
14.2%
16.3%
17.5%
19.4%
12.8%
5.4%
2.9%
2.4%
1.1%
1.2%
13.4%
14.7%
23.2%
24.0%
16.8%
7.9%

20
219
419
309
105

1.9%
20.4%
39.1%
28.8%
9.8%

Abbreviations: SD, standard deviation; IQR, interquartile range.
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89% were white. Forty-one percent had at least a four-year
college education and just under half (45%) had an annual
income of $50,000 or more. Hypertension and hyperlipidemia
were each reported by about a quarter of respondents (24%
and 23%, respectively). A smaller percentage of respondents
had osteoporosis (17%), diabetes (15%), asthma (13%), or
other CVD (8%). A majority of the samples rated their health
as good (39.1%) or fair (28.8%).

Results of SEM
Table 2 presents the standardized path coefficients from the
SEM model for the proximal treatment beliefs. Goodness
of fit indices showed good model fit with CFI = 0.973,
RMSEA = 0.031 and SRMR = 0.032. The chi-square test
was statistically significant (chi-square = 248, df = 121,
P , 0.0001), reflecting a relatively good model fit72 given the
sample size and deviations from multivariate normality.73–75
The model fit was much improved compared to the baseline
full model (chi-square = 299, df = 24, RMSEA = 0.104)
and an alternative model without considering modifications
(chi-square = 324, df = 109, RMSEA = 0.043).
Greater perceived need for medications was related to
greater perceived disease severity (β = 0.480), less value
placed on nutraceuticals (β = -0.249), more knowledge
about the index medication (β = 0.244), greater patient
engagement in their care (β = 0.137), more perceived
immunity to side effects (β = 0.119), and less information
seeking (β = -0.090). In addition, age was positively related
to perceived need for medications. Compared to patients
with hypertension, those with dyslipidemia, osteoporosis,
or other CVD perceived less need for the index medication.
Over two-thirds (68.3%) of the variation in perceived need
for medications was explained by these eight significant
predictors.
Fewer medication concerns were associated with more
perceived immunity to side effects (β = 0.353), less value
placed on nutraceuticals (β = -0.318), more knowledge about
the index medication (β = 0.164), greater patient engagement in their care (β = 0.125), less information seeking
(β = -0.084), less perceived disease severity (β = -0.078),
and less of an internal locus of control (β = -0.051). As
age increased, medication concerns decreased. Compared
to patients with hypertension, those with dyslipidemia
or osteoporosis had more medication concerns. One-half
(50.9%) of the variation in perceived medication concerns
was explained by these nine significant predictors.
Better medication affordability was related to less
perceived disease severity (β = -0.233), greater income
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Table 2 Standardized path loadings of path model in predicting proximal beliefs
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Independent
variables

Perceived disease severity
Patient knowledge
Perceived side-effect immunity
Perceived value of nutraceuticals
Patient engagement
Information seeking
Internal health locus of control
Self-rated health
Mental health
Age
Female
White race
Education
Income
Asthma
Diabetes
Lipid
Osteoporosis
Other CVD
R-square of model

Perceived need for
medications

Perceived medication
concerns

Perceived medication
affordability

Standardized β

SE

Standardized β

SE

Standardized β

SE

0.480‡
0.244‡
0.119‡
-0.249‡
0.137‡
-0.090‡
NS
NS
NS
0.065‡
NS
NS
NS
NS
NS
NS
-0.059‡
-0.081‡
-0.045±
0.683

0.021
0.031
0.023
0.025
0.027
0.021
NS
NS
NS
0.018
NS
NS
NS
NS
NS
NS
0.018
0.020
0.017
0.016

-0.078
0.164‡
0.353‡
-0.318‡
0.125‡
-0.084±
-0.051*
NS
NS
0.094‡
NS
NS
NS
NS
NS
NS
-0.053*
-0.059±
NS
0.509

0.026
0.032
0.024
0.030
0.032
0.027
0.021
NS
NS
0.023
NS
NS
NS
NS
NS
NS
0.022
0.022
NS
0.023

-0.233
0.082±
NS
-0.222‡
NS
NS
NS
0.136‡
0.101±
0.166‡
-0.072±
NS
0.057*
0.231‡
NS
NS
NS
NS
NS
0.340

0.030
0.029
NS
0.029
NS
NS
NS
0.032
0.031
0.026
0.026
NS
0.028
0.031
NS
NS
NS
NS
NS
0.023

±

‡

Notes: ‡P , 0.001; ±P , 0.01; *P , 0.05; goodness of model fit: P-values listed in parentheses; estimator = MLR; 127 free parameters; Chi-square = 248.122 (df = 121) with
P-value , 0.0001; CFI = 0.973; RMSEA = 0.031; 90% CI = (0.026, 0.037); SRMR = 0.032.
Abbreviations: CVD, cardiovascular disease; NS, nonsignificant; SE, standard error; MLR, maximum likelihood with robust standard errors; CFI, comparative fit index;
RMSEA, root mean square error of approximation; SRMR, standardized root mean square residual.

(β = 0.231), less value placed on nutraceuticals (β = -0.222),
older age (β = 0.166), better self-rated health (β = 0.136), better mental health (β = 0.101), and more knowledge about the
index medication (β = 0.082). Females found medications to
be less affordable, while education was positively related to
perceived medication affordability. One-third (34.0%) of the
variation in perceived medication affordability was explained
by these nine significant predictors.
The four intermediate beliefs were then modeled as
dependent variables (Table 3). Greater perceived disease
severity was related to worse self-rated health (β = -0.262),
greater patient engagement in their care (β = 0.254), greater
information seeking (b = 0.122), and worse mental health
(b = -0.112). As education increased, perceptions of disease severity decreased. Compared to patients with hypertension, those with asthma or osteoporosis perceived their
diseases to be less severe, while those with other CVD and
diabetes perceived their conditions to be more severe. Onequarter (25.1%) of the variation in perceived disease severity
was explained by these six significant predictors.
Greater knowledge about the index medication was
related to greater patient engagement in their care (β = 0.521),
greater information-seeking tendencies (β = 0.325), more of
794
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an internal locus of control (β = 0.062), and better mental
health (β = 0.047). Close to one-half (47.7%) of the variation
in knowledge about the index medication was explained by
these four predictors.
Greater perceived immunity to side effects was associated
with greater patient engagement in their care (β = 0.259),
less information-seeking tendencies (β = –0.242), and better mental health (β = 0.119). Men felt more immune to
side effects. As education increased, perceived immunity
to side effects increased. Fifteen percent of the variation in
perceived immunity to side effects was explained by these
five predictors.
More value placed on nutraceuticals was associated
with less patient engagement in care (β = -0.415), a greater
internal locus of control (β = 0.209), greater informationseeking tendencies (β = 0.126), and better self-rated health
(β = 0.100). Younger persons, nonwhites, and respondents
with osteoporosis or asthma placed greater value on nutraceuticals compared to those with hypertension. As both
education and income increased, value placed on nutraceuticals decreased. Over one-quarter (28.6%) of the variation
in perceived value of nutraceuticals was explained by these
predictors.
Patient Preference and Adherence 2012:6
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Table 3 Standardized path loadings of path model in predicting intermediate beliefs
Independent
variables

Intermediate beliefs

Standardized β

SE

Standardized β

Patient engagement
Health information seeking
Internal health locus of control
Self-rated health
Mental health
Age
Female
White race
Education
Income
Asthma
Diabetes
Lipid
Osteoporosis
Other CVD
R square for model

0.254‡
0.122‡
NS

0.029
0.028
NS
0.030
0.030
NS
NS
NS
0.027
NS
0.031
0.026
NS
0.029
0.026
0.023

0.521‡
0.325‡

Perceived disease
severity

-0.262‡
-0.112‡
NS
NS
NS
-0.105‡
NS
-0.074*
0.130‡
NS
-0.103‡
0.094‡
0.251

Patient
knowledge

0.062±
NS
0.047*
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
0.477

Perceived side-effect
immunity

Perceived value of
nutraceuticals

SE

Standardized β

SE

Standardized β

SE

0.023
0.026
0.024
NS
0.021
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
0.025

0.259‡

0.030
0.030
NS
NS
0.029
NS
0.027
NS
0.028
NS
NS
NS
NS
NS
NS
0.020

-0.415
0.126‡
0.209‡
0.100‡
NS

0.026
0.029
0.026
0.028
NS
0.025
NS
0.025
0.028
0.029
0.026
NS
NS
0.025
NS
0.024

-0.242
NS
NS
0.119‡
NS

‡

-0.111‡
NS
0.126‡
NS
NS
NS
NS
NS
NS
0.151

‡

-0.084±
NS
-0.053*
-0.083±
-0.122‡
0.060*
NS
NS
0.128‡
NS
0.286

Notes: ‡P , 0.001; ±P , 0.01; *P , 0.05; goodness of model fit: P-values listed in parentheses; estimator = MLR; 127 free parameters; Chi-square = 248.122 (df = 121) with
P-value , 0.0001; CFI = 0.973; RMSEA = 0.031; 90% CI = (0.026, 0.037); SRMR = 0.032.
Abbreviations: CVD, cardiovascular disease; NS, nonsignificant; SE, standard error; MLR, maximum likelihood with robust standard errors; CFI, comparative fit index;
RMSEA, root mean square error of approximation; SRMR, standardized root mean square residual.

Determinants of the more distal generic beliefs are
presented in Table 4. The more distal generic beliefs were
predominately influenced by age and disease. Older adults
and respondents with asthma were more engaged in their
care compared to responders with hypertension (R2 = 0.037).
Greater information-seeking tendency was associated with
female gender, more education, older age, and having asthma
or other CVD compared to hypertension (R 2 = 0.077).
Internal locus of control was associated with less education
and nonwhite race (R2 = 0.014). Better self-rated health was
associated with higher income, older age, and a lower likelihood of other CVD or diabetes compared to hypertension
(R2 = 0.121). Finally, better mental health was associated
with older age and higher income (R2 = 0.107).

Discussion
Over the past 40 years, research on the determinants of
medication adherence has gradually shifted from a focus
on generic health beliefs to beliefs specific to a treatment
and a disease. The Necessity-Concerns Framework6 and
Proximal–Distal Continuum9 are two frameworks that hold
that medication adherence is more powerfully explained by
treatment-specific than by generic beliefs. Generic beliefs, in
turn, are useful in understanding the determinants of diseasespecific beliefs. To the best of the authors’ knowledge, this is
the first study that has concurrently modeled the predictors
Patient Preference and Adherence 2012:6

of treatment-specific, proximal medication beliefs: perceived
need for medications, perceived medication concerns, and
perceived medication affordability.
Numerous hypotheses were tested in the SEM modeling of the proximal–distal continuum. However, only a few
components of the proximal–distal continuum consistently
emerged as statistically-significant predictors with relatively
large path coefficients (perceived disease severity, patient
knowledge, perceived side-effect immunity, perceived
value of nutraceuticals, and patient engagement). These
five variables are also the most clinically mutable beliefs
and skills in the proximal–distal continuum. Because so
few studies have studied the determinants of treatmentspecific beliefs, we contextualize these results largely with
past research on medication adherence and discuss their
implications for adherence communication and adherence
interventions.
Three of the intermediate, independent variables –
perceived disease severity, knowledge about the index
medication, and perceived value of nutraceuticals – were
significantly associated with all three proximal adherence
drivers. Perceived disease severity – or the potential for a
condition to cause physical, mental or psychosocial harm –
is a significant component of most social-cognitive models
of medication taking.2 Consistent with past research,18–21,76,77
perceived disease severity was a significant predictor of the
submit your manuscript | www.dovepress.com
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Notes: ‡P , 0.001; ±P , 0.01; *P , 0.05; goodness of model fit: P-values listed in parentheses; estimator = MLR; 127 free parameters; Chi-square = 248.122 (df = 121) with P-value , 0.0001; CFI = 0.973; RMSEA = 0.031; 90% CI =
(0.026, 0.037); SRMR = 0.032.
Abbreviations: CVD, cardiovascular disease; NS, nonsignificant; SE, standard error; MLR, maximum likelihood with robust standard errors; CFI, comparative fit index; RMSEA, root mean square error of approximation; SRMR,
standardized root mean square residual.

0.025
NS
NS
NS
0.029
NS
NS
NS
NS
NS
0.016
0.308
NS
NS
NS
0.121‡
NS
NS
NS
NS
NS
0.107
0.026
NS
NS
NS
0.027
NS
0.026
NS
NS
0.025
0.018
0.147
NS
NS
NS
0.245‡
NS
-0.121‡
NS
NS
-0.180‡
0.121
NS
NS
0.027
0.030
NS
NS
NS
NS
NS
NS
0.007
0.169
NS
NS
NS
NS
0.089‡
NS
NS
NS
NS
0.037
Age
Female
White race
Education
Income
Asthma
Diabetes
Lipid
Osteoporosis
Other CVD
R square for model

‡

0.030
0.030
NS
0.029
NS
0.026
NS
NS
NS
0.027
0.016
0.070*
0.218‡
NS
0.127‡
NS
0.065*
NS
NS
NS
0.096‡
0.077
0.027
NS
NS
NS
NS
0.026
NS
NS
NS
NS
0.010

NS
NS
-0.069*
-0.098‡
NS
NS
NS
NS
NS
NS
0.014*

Standardized β

‡
‡

Mental health

SE
Self-rated health

Standardized β
SE
Standardized β
Standardized β

SE

Health information seeking

SE
Standardized β

Internal health locus of control
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Distal beliefs

Independent
variables

Table 4 Standardized path loadings of path model in predicting distal beliefs
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three proximal treatment beliefs, but particularly of perceived
need for medications. Patients who perceive their disease
to be more severe may appreciate the long-term value of
therapy, thus strengthening their intrinsic commitment to
medication taking. Patients who perceive their disease to be
more severe might be taking multiple medications, thereby
making medications less affordable and raising concerns
about medication side effects and medication interactions.
Greater disease severity has been directly linked to improved
medication adherence in numerous studies78–82 including
a meta-analysis.83 Lack of perceived disease severity was
cited as a reason for both medication nonfulfillment and
nonpersistence in a study of US adults with chronic disease.62
Patients need to understand the severity of their condition
in order to internalize the rationale for therapy and develop
ego commitment to the medication. Health care providers
are uniquely qualified to convey to patients the potential
severity of their conditions as well as short- and long-term
consequences of undertreated or untreated chronic disease.
Educational-based adherence interventions should explicitly
address disease severity as a content area and assess patient
understanding using well-established, patient-centered communication techniques.
In this study, patients with more knowledge about the
index medication had significantly greater commitment to
(need for) the medication, fewer medication concerns, and
greater perceived medication affordability. The largest effect
was observed for perceived need for the medication. Patient
knowledge has been positively linked with medication adherence in many studies.51,84–92 Information/knowledge is one of
the troika of adherence drivers in two adherence conceptual
frameworks – the Information-Motivation-Behavioral Skills
model7 and the Information-Motivation-Strategy model.8
Lack of knowledge about the disease and/or prescribed
therapy has been reported by patients as a reason for medication nonfulfillment or nonpersistence.93–96
Both qualitative97–101 and quantitative102–106 research has
revealed that many patients lack knowledge about their diagnosed conditions, the potential severity of their conditions,
and the consequences of lack of treatment. Patients also frequently report a lack of information about newly prescribed
medications.43,102,103,107–116 Without sufficient knowledge about
their condition, its potential severity, and the rationale for the
prescribed medication, many patients may find it difficult to
identify with (be ego involved with) the diagnosis and therapy
and to accept therapy with a sense of autonomous choice.
When uncertainty and ambiguity are high, people tend to
pessimistically evaluate the risk and benefits of therapy.117
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Thus, lack of information and knowledge about the diagnosed
condition and the prescribed therapy can exacerbate patients’
uncertainty and ambivalence about prescription medications
and can inhibit their internalization of their condition as
chronic in nature.
Past educational/knowledge-based adherence interventions have tended to have small effect sizes.118 This
finding may be due to education and knowledge being
operationalized and delivered differently across studies (eg,
as disease knowledge, risk-factor knowledge, medication
knowledge, and/or regimen knowledge) and the possibility
that knowledge may more powerfully predict the proximal
determinants of adherence –perceived need, concerns, and
affordability – than adherence per se. Further, few adherence interventions have involved patients in the design and
content of the intervention. Future adherence interventions
should be truly patient-centered and involve patients a priori
in determining what is needed, how much is needed, for
how long, and via what channel. It is plausible that what
newly diagnosed heart failure patients require in terms of
information may be quantitatively and qualitatively different
from what breast cancer patients newly prescribed adjuvant
hormonal therapy need and prefer. Future adherence interventions should conceptualize knowledge in a multifactorial
sense and deliver it longitudinally via a variety of channels
and settings.119
Many past knowledge-based adherence interventions
have been of short duration with only a handful or less of
interventional touch points. Future adherence interventions
should focus on the first two months of therapy, when the
risk of nonpersistence is greatest. Multiple interventional
touch points can reinforce learning and help minimize
uncertainty. Disease knowledge (etiology, severity, course,
and sequelae) and medication knowledge (rationale, duration of therapy, alternative therapies, risks and benefits, and
consequences of nonadherence) need to be communicated
in health–literacy appropriate ways. Such knowledge could
be delivered with patient-centered decision aids or tools
that attempt to present unbiased and complete information
about the potential benefits and downsides of treatment
choices.120 The promise of patient-centered decision aids
for prescription medications lies in the hope that, through
their use, providers will be preparing patients for treatment
and involving them in the treatment process. Patients may
more readily and consistently accept treatment if they feel
the decision to start therapy is their choice rather than the
provider’s directive.121 Finally, it is important to underscore
the difference between information/knowledge and patient
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understanding. Patients can only do what they understand.8
Numerous patient-centered techniques are available to gauge
patient understanding, such as “teach-back,”122 “ask-tellask,”123 and “elicit-provide-elicit.”124 These techniques could
not only be used in adherence interventions but in routine
clinical practice as well at the time of prescribing. In one
study, physicians trained in ask-tell-ask were able to successfully employ the technique without statistically increasing
the median visit length.125
A novel finding from this study is that respondents who
placed more value on nutraceuticals (vitamins, supplements,
and minerals) had lower perceived need for medications,
more medication concerns, and less perceived medication
affordability. Some adults believe over-the-counter and
herbal remedies are less risky than prescription medications
and that they are natural, safe, familiar, and can be used
with less risk.126–128 Gascon100 found that there was greater
confidence in herbal or natural remedies than in prescription
medicines to treat hypertension. Other research has found
use of complementary and alternative medicine (CAM) to
be associated with suboptimal medication-effectiveness
beliefs129 and worse medication adherence.130–134 Favorable
attitude toward CAM has been reported to be associated
with worse adherence intentions.135 Thus, some adults may
be substituting pharmaceuticals with nutraceuticals.
An uncertainty lens helps to explain why some patients
migrate toward nutraceuticals and alternative medicine for
the self-management of chronic disease – they are viewed as
doing something good for oneself (“natural” remedies) and
as actions involving little risk and little threat to the status
quo. Internet website and print communications abound with
advertisements that claim to treat or cure chronic disease
naturally. Past research has shown that providers are not
proactive in discussing nutraceuticals and CAM,131,136 and
that patients do not proactively disclose their nutraceutical
and CAM use to their providers.137,138 Physicians, pharmacists, and interventionists should proactively address use of
nutraceuticals with patients and communicate their relative
clinical efficacy for the treatment of chronic disease compared to prescription medications. Future research should
better understand the role of nutraceuticals specifically, and
CAM generally, in patients’ adherence decisions.
Perceived side-effect immunity was a signif icant
predictor of perceived need and perceived concerns but not
affordability. Perceived side-effect immunity was the most
important predictor of perceived medication concerns. Other
research has linked perceived sensitivity to side effects with
enhanced medication concerns.6,77 Fear of side effects and
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perceived side-effect susceptibility have been documented
in the literature as reasons for medication nonadherence
(nonfulfillment or nonpersistence)62,139–145 and noncompliance (usage deviations).146 Little is known about how or why
patients come to feel susceptible to side effects. However,
research has documented that patients report significant unmet
need for side-effect information.110,147–149 Physicians express
concern that disclosure of side-effect information will increase
patients’ report and/or experience of side effects through the
effect of suggestability.150–154 However, extant research has
refuted this line of reasoning: side-effect forewarning through
verbal or written information has not been shown to increase
reports of side effects.155–161 On the contrary, patients have
relayed that, armed with information about side effects, they
would be less likely to become alarmed should a side effect
occur and would have fewer concerns about them.162–164 In
one study, patients reported that detailed disclosure about side
effects would make them feel more confident in the physician
(94%), more likely to adhere to treatment (91%), and more
confident in the medication (82%).150
Unaddressed medication concerns and fear of side effects
can intensify patients’ uncertainty especially when the potential benefits of medication therapy have not been appropriately communicated and when potential benefits do not occur
immediately, as with most asymptomatic chronic conditions.
Providers should disclose common side effects and create a
plan with patients that addresses what they should do should
a side effect occur.165 Such collaborative communication
behaviors are consistent with patient-centered care and shared
decision making. Adherence interventionists can employ
patient-centered decision aids to communicate both the pros
and cons of treatment in a balanced manner.
Our measure of patient engagement assessed patient
trust in their provider and patient involvement in their care.
In this study, patient engagement was a significant predictor
of six of the seven outcomes (all but perceived medication
affordability). Patients who were more engaged in their care
had a greater perceived need for medications, fewer medication concerns, perceived their disease to be more severe,
had more knowledge about the index medication, felt more
immune to side effects, and valued nutraceuticals less. The
greatest impact was on prescription-medication knowledge.
In women with osteoporosis, Schousboe et al20 also found
patient engagement to be significantly related to greater perceived need for medications and fewer medication concerns.
Two other studies reported patient trust to be associated with
better medication beliefs,21,166 a finding similar to our observed
results. Both patient trust167–171 and patient involvement172–174
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have been demonstrated in past research to be associated with
improved medication adherence. Two recent meta-analyses
concluded that better physician–patient collaboration175 and
better physician communication176 significantly influence
medication adherence.
Patient engagement is a key foundational element of
patient-centered care and shared decision making. Past
research has shown that patients can be coached to be more
proactively involved in their care.177–185 Involving patients
in medication-therapy decision making may increase their
intrinsic motivation and ego involvement in treatment.
A simple way to engage patients is to ask whether they are
ready to commit to therapy. Patients’ expression of uncertainty or ambivalence is a marker for unresolved concerns or
unmet information needs. Patient-centered decision aids for
prescription medications may be a cost- and time-effective
way of increasing patient engagement in their treatment in
both clinical practice and in adherence interventions.
Although numerous hypotheses were tested in the SEM
modeling of the proximal–distal continuum, none of the
observed results were anomalous. In the vast majority of
findings, coefficient signs were in the expected direction.
As a predictor variable, the multi-item scale assessing
health-information seeking yielded three results that could
have plausibly been either positive or negative. Patients
with greater health–information seeking tendencies had less
perceived need for medications (Table 2), more perceived
medication concerns, (Table 2), and less perceived immunity
to side effects (Table 3). While health-information seeking
was significantly and positively related to greater patient
knowledge (Table 3), it is possible that health-information
seeking could generate negative or even conflicting information, which could then dampen perceived need, elevate medication concerns, and elevate susceptibility to side effects.

Study strengths and limitations
There are both strengths and limitations to the study. In terms
of strengths, use of the proximal–distal continuum was based
upon both conceptual and empirical learning accumulated
over the past 40 years. A large, internet-based panel of adults
with chronic disease was accessed with representation from
47 of the 50 US states. Most of the multi-item scales were
highly internally consistent (range of Cronbach’s alpha of
0.76 to 0.97, median = 0.91). We had a large sample size
(n = 1072) upon which to test the SEM model.
In terms of limitations, the survey contact rate (26.5%)
was low. Survey noncontact analysis indicated that persons
aged 55 years and older, whites, and those with at least a
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college degree were more likely to be successfully contacted
than their respective counterparts.9 The obtained internetbased sample was slightly underrepresented by adults with
income less than $25,000 annually compared to the US
adult population.186 Also, relative to the US adult population
aged 25 years and older,187,188 the obtained sample had an
underrepresentation of adults with less than a high-school
education, an overrepresentation of adults with at least a
college degree, and overrepresentation of whites. Because
of these demographic differences between the obtained
sample and the US general adult population, generalizability of our results to the broader US population may not be
appropriate. An Internet panel was used, which also may
limit generalizability. The study was cross sectional. As a
result of the cross-sectional design, no inferences regarding
causality of the elements of the proximal–distal continuum
can be made. The study involved adults with self-identified
chronic disease. None of the six study conditions were
substantiated with medical records. On the other hand,
a well-defined, chronic disease panel was accessed and the
six conditions were reverified using a separate, independent
screener than was used to enroll the Chronic Illness Panel.
Only six conditions were studied, although they are highly
prevalent in the US adult population. No psychiatric conditions were studied. The array of adherence drivers tested in
the proximal–distal continuum was not exhaustive of the
200 putative adherence determinants.189 We did not study
some adherence determinants included in other research,
such as self-efficacy, social support, symptom severity,
the experience of side effects, side-effect severity, length
of time with the diagnosis, and length of time in treatment
with prescription-medication therapy. We only tested the
proximal–distal continuum and did not test alternative
theoretical models of adherence drivers.

Conclusion
For decades now, nonadherence has been among the most
significant problems facing medical practice.190 Nonadherence
is a psychosocial marker that issues important to patients
were not addressed – that patients have unvoiced uncertainties and ambivalence about their condition and prescribed
therapy. In clinical practice, a shroud of silence envelopes
the topic of medication adherence: physicians often do not
proactively ask about adherence and patients frequently do
not tell them when they fail to fill a new prescription or stop
therapy on their own.9 Thus, patients are largely alone with
their doubts and uncertainties. For long-term medication
adherence, patients need to autonomously and intrinsically
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commit to therapy and this is more likely to occur when they
are informed (about disease knowledge, disease severity,
medication knowledge and rationale, consequences of nonadherence, and side effects), understand, and are motivated
(engaged in their care, perceive a need for medication, and
believe the benefits outweigh the risks). In short, intuitively
patient-centered strategies are needed to help patients to
know what their condition is, why the medication is needed,
how the prescribed therapy may help, and how the benefits
may outweigh the risks.
Testing the proximal–distal continuum of adherence drivers sheds light on specific areas where adherence dialogue
and enhancement could focus. Our results can help to inform
the design of future adherence interventions, as well as the
content of patient-education materials and adherence reminder
letters. An important learning from testing the proximal–distal
continuum is that future adherence interventions need to move
from manipulating single adherence barriers to interceding in a
multidimensional space. Results also suggest that intervening
along the etiological continuum of patient beliefs, states, and
skills may more optimally improve adherence than intervening in a single causal space. Interventions that focus on distal
beliefs, states, and skills should be deprioritized. Instead of
assuming a one-size-fit-all design, future adherence interventions should target persons who are deficit in the proximal
determinants of adherence: perceived need for medications,
perceived medication concerns, and perceived medication
affordability. In addition, it should be possible to target patients
or tailor interventions using the most important sociomedical
predictors identified in this study: perceived disease severity,
patient knowledge, perceived side-effect immunity, perceived
value of nutraceuticals, and patient engagement.
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